Key result
Blockade of the renin-angiotensin system with ACE inhibitors or angiotensin II antagonists reduces renal and cardiovascular events and delays the progression of diabetic nephropathy.
Why the study?
Does blockade of the renin-angiotensin system with ACEi or angiotensin II antagonists reduce renal and cardiovascular events in patients with diabetes?
Does blockade of the renin-angiotensin system with ACEi or angiotensin II antagonists reduce renal and cardiovascular events in patients with diabetes?
RAAS blockade with ACE inhibitors or angiotensin II antagonists provides significant cardiovascular and renoprotective benefits in patients with diabetes, delaying the progression of diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Supports RAAS blockade in diabetes; leaves open optimal regimens versus newer agents in contemporary cohorts.
Burnier et al. (2005) conducted a review in Diabetes (particularly type 2 diabetes) and diabetic nephropathy. Blockade of the renin-angiotensin system with ACE inhibitors or angiotensin II antagonists was evaluated. Blockade of the renin-angiotensin system with ACE inhibitors or angiotensin II antagonists reduces renal and cardiovascular events and delays the progression of diabetic nephropathy.